Research progress on metabonomics biomarkers of major depressive disorder
QI Yonghua SUN Hui WANG Xijun
Research Center of Traditional Chinese Medicine Prescription Metabolomics, National Administration of Traditional Chinese Medicine, Heilongjiang University of Chinese Medicine, Heilongjiang Province, Harbin 150040, China
Abstract：Major depressive disorder (MDD) is a major mental disorder worldwide, it causes enormous economic and emotional stress on society. The discovery of biomarkers can not only improve the diagnosis of depression and accelerate the development of new drugs, but also be used to predict the likelihood of depression and advance the process of personalized treatment of MDD. In recent years, the rapid development of metabolomics and its extensive application in disease diagnosis have provided the possibility for further screening of MDD related biomarkers. This paper will summarize and discuss the research progress of metabonomics biomarkers in the MDD based on the metabolomics of blood, urine and cerebrospinal fluid, with the purpose of enabling researchers to make new discoveries on the basis of existing studies, and expect the biomarker of MDD to play an important role in clinical practice as soon as possible to improve the quality of life of MDD patients.
祁永华 孙晖 王喜军. 重度抑郁症的代谢组学生物标志物研究进展[J]. 中国医药导报, 2020, 17(12): 49-52.
QI Yonghua SUN Hui WANG Xijun. Research progress on metabonomics biomarkers of major depressive disorder. 中国医药导报, 2020, 17(12): 49-52.
[1] Phillips ML，Chase HW，Sheline YI，et al. Identifying Predictors，Moderators，and Mediators of Antidepressant Response in Major Depressive Disorder：Neuroimaging Approaches [J]. Am J Psychiatry，2015，172（2）：124-138.
[2] Kunugi H，Hori H，Ogawa S. Biochemical markers subtyping major depressive disorder [J]. Psychiatry Clin Neurosci，2015，69（10）597-608.
[3] Smith K. Mental health：a world of depression [J]. Nature，2014，515（7526）：181.
[4] Penninx BW，Milaneschi Y，Lamers F，et al. Understanding the somatic consequences of depression：biological mechanisms and the role of depression symptom profile [J]. BMC Med，2013，11：129.
[5] Dean J，Keshavan M. The neurobiology of depression：An integrated view [J]. Asian J Psychiatr，2017，27：101-111.
[6] Papakostas GI，Shelton RC，Kinrys G，et al. Assessment of a multi-assay，serum-based biological diagnostic test for major depressive disorder：a Pilot and Replication Study [J]. Mol Psychiatr，2013，18（3），332-339.
[7] Bartova L，Berger A，Pezawas L. Is there a personalized medicine for mood disorders? [J]. Eur Arch Psychiatry Clin Neurosci，2010，260 Suppl 2：121-126.
[8] Olfson M，Marcus SC. National patterns in antidepressant medication treatment [J]. Arch Gen Psychiatry，2009，66（8）：848-856.
[9] Ball S，Classi P，Dennehy EB. What happens next?：a claims database study of second-line pharmacotherapy in patients with major depressive disorder（MDD）who initiate selective serotonin reuptake inhibitor（SSRI）treatment [J]. Ann Gen Psychiatry，2014，13（1）：8.
[10] Warden D，Rush AJ，Trivedi MH，et al. The STAR*D Project results：a comprehensive review of findings [J]. Curr Psychiatry Rep，2007，9（6）：449-459.
[11] Craighead WE，Dunlop BW. Combination psychotherapy and antidepressant medication treatment for depression：for whom，when，and how [J]. Annu Rev Psychol，2014， 65：267-300.
[12] Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints：Preferred definitions and conceptual framework [J]. Clin Pharmacol Ther，2001，69（3）：89-95.
[13] Beauchaine TP. Role of biomarkers and endophenotypes in prevention and treatment of psychopathological disorders [J]. Biomarker Med，2009，3（1）：1-3.
[14] Martins-de-Souza D. Proteomics，metabolomics，and protein interactomics in the characterization of the molecular features of major depressive disorder [J]. Dialogues Clin Neurosci，2014，16（1）：63-73.
[15] Pan JX，Xia JJ，Deng FL，et al. Diagnosis of major depressive disorder based on changes in multiple plasma neurotransmitters：a targeted metabolomics study [J]. Transl Psychiatry，2018，8（1）：130.
[16] Kawamura N，Shinoda K，Sato H，et al. Plasma metabolome analysis of patients with major depressive disorder [J]. Psychiatry Clin Neurosci，2018，72（5）：349-361.
[17] Zhou X，Liu L，Lan X，et al. Polyunsaturated fatty acids metabolism，purine metabolism and inosine as potential independent diagnostic biomarkers for major depressive disorder in children and adolescents [J]. Mol Psychiatry，2019，24（10）：1478-1488.
[18] Kuwano N，Kato TA，Setoyama D，et al. Tryptophan-kynurenine and lipid related metabolites as blood biomarkers for first-episode drug-na?觙ve patients with major depressive disorder：An exploratory pilot case-control study [J]. J Affect Disord，2018，231：74-82.
[19] Liu H，Ding L，Zhang H，et al. The metabolic factor kynurenic acid of kynurenine pathway predicts major depressive disorder [J]. Front Psychiatry，2018，9：552.
[20] Zheng P，Fang Z，Xu XJ，et al. Metabolite signature for diagnosing major depressive disorder in peripheral blood mononuclear cells [J]. J Affect Disord，2016，195：75-81.
[21] Zheng P，Wang Y，Chen L，et al. Identification and validation of urinary metabolite biomarkers for major depressive disorder [J]. Mol Cell Proteomics，2013，12（1）：207-214.
[22] Chen JJ，Zhou CJ，Zheng P，et al. Differential urinary metabolites related with the severity of major depressive disorder [J]. Behav Brain Res，2017，332：280-287.
[23] Bromet E，Andrade LH，Hwang I，et al. Cross-national epidemiology of DSM-Ⅳ major depressive episode[J]. BMC Med，2011，9：90.
[24] Zheng P，Chen JJ，Zhou CJ，et al. Identification of sex-specific urinary biomarkers for major depressive disorder by combined application of NMR- and GC–MS-based metabonomics [J]. Transl Psychiatry，2016，6（11）：e955.
[25] Chen JJ，Xie J，Li WW，et al. Age-specific urinary metabolite signatures and functions in patients with major depressive disorder [J]. Aging（Albany NY），2019，11（17）：6626-6637.
[26] Yoon HS，Hattori K，Ogawa S，et al. Relationships of Cerebrospinal Fluid Monoamine Metabolite Levels With Clinical Variables in Major Depressive Disorder [J]. J Clin Psychiatry，2017，78（8）：e947-e956.
2020, Vol. 17 
京公网安备 11010502046598号